Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study.
Cristiana CiprianiSara PiemonteLuciano ColangeloViviana De MartinoDaniele DiacintiFederica FerroneValentina PiazzollaValeria FassinoLuciano NiedduSalvatore MinisolaJessica PepePublished in: Endocrine (2020)
24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.